Literature DB >> 24048214

Prevention and control of seasonal influenza with vaccines. Recommendations of the Advisory Committee on Immunization Practices--United States, 2013-2014.

.   

Abstract

This report updates the 2012 recommendations by CDC's Advisory Committee on Immunization Practices (ACIP) regarding the use of influenza vaccines for the prevention and control of seasonal influenza (CDC. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices [ACIP]. MMWR 2012;61:613-8). Routine annual influenza vaccination is recommended for all persons aged ≥ 6 months. For the 2013-14 influenza season, it is expected that trivalent live attenuated influenza vaccine (LAIV3) will be replaced by a quadrivalent LAIV formulation (LAIV4). Inactivated influenza vaccines (IIVs) will be available in both trivalent (IIV3) and quadrivalent (IIV4) formulations. Vaccine virus strains included in the 2013-14 U.S. trivalent influenza vaccines will be an A/California/7/2009 (H1N1)-like virus, an H3N2 virus antigenically like the cell-propagated prototype virus A/Victoria/361/2011, and a B/Massachusetts/2/2012-like virus. Quadrivalent vaccines will include an additional influenza B virus strain, a B/Brisbane/60/2008-like virus, intended to ensure that both influenza B virus antigenic lineages (Victoria and Yamagata) are included in the vaccine. This report describes recently approved vaccines, including LAIV4, IIV4, trivalent cell culture-based inactivated influenza vaccine (ccIIV3), and trivalent recombinant influenza vaccine (RIV3). No preferential recommendation is made for one influenza vaccine product over another for persons for whom more than one product is otherwise appropriate. This information is intended for vaccination providers, immunization program personnel, and public health personnel. These recommendations and other information are available at CDC's influenza website (http://www.cdc.gov/flu); any updates also will be found at this website. Vaccination and health-care providers should check the CDC influenza website periodically for additional information.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24048214

Source DB:  PubMed          Journal:  MMWR Recomm Rep        ISSN: 1057-5987


  207 in total

1.  Legal Authority for Infectious Disease Reporting in the United States: Case Study of the 2009 H1N1 Influenza Pandemic.

Authors:  Richard N Danila; Ellen S Laine; Franci Livingston; Kathryn Como-Sabetti; Lauren Lamers; Kelli Johnson; Anne M Barry
Journal:  Am J Public Health       Date:  2015-01       Impact factor: 9.308

2.  Influenza Vaccine Effectiveness in a Low-Income, Urban Community Cohort.

Authors:  Marie Smithgall; Celibell Y Vargas; Carrie Reed; Lyn Finelli; Philip LaRussa; Elaine L Larson; Lisa Saiman; Melissa S Stockwell
Journal:  Clin Infect Dis       Date:  2015-09-28       Impact factor: 9.079

Review 3.  Vaccination of adolescents with chronic medical conditions: Special considerations and strategies for enhancing uptake.

Authors:  Annika M Hofstetter; Philip LaRussa; Susan L Rosenthal
Journal:  Hum Vaccin Immunother       Date:  2015-07-25       Impact factor: 3.452

Review 4.  Vaccination of healthcare workers: A review.

Authors:  Skerdi Haviari; Thomas Bénet; Mitra Saadatian-Elahi; Philippe André; Pierre Loulergue; Philippe Vanhems
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

5.  Current status and uptake of influenza vaccination over time among senior adults in the United States.

Authors:  Peng-Jun Lu; Alissa O'Halloran; Helen Ding; Stacie M Greby; Walter W Williams
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

6.  Circulation of influenza B lineages in northern Viet Nam, 2007-2014.

Authors:  Thi Thanh Le; Thu Hang Pham; Thi Hien Pham; Le Khanh Hang Nguyen; Co Thach Nguyen; Vu Mai Phuong Hoang; Thu Huong Tran; Vu Son Nguyen; Huong Giang Ngo; Quynh Mai Le
Journal:  Western Pac Surveill Response J       Date:  2015-11-11

7.  Association of Influenza Vaccination Coverage in Younger Adults With Influenza-Related Illness in the Elderly.

Authors:  Glen B Taksler; Michael B Rothberg; David M Cutler
Journal:  Clin Infect Dis       Date:  2015-09-09       Impact factor: 9.079

8.  Toll-like receptor 7 agonist imiquimod in combination with influenza vaccine expedites and augments humoral immune responses against influenza A(H1N1)pdm09 virus infection in BALB/c mice.

Authors:  Anna J X Zhang; Can Li; Kelvin K W To; Hou-Shun Zhu; Andrew C Y Lee; Chuan-Gen Li; Jasper F W Chan; Ivan F N Hung; Kwok-Yung Yuen
Journal:  Clin Vaccine Immunol       Date:  2014-02-12

9.  Clinical differences of influenza subspecies among hospitalized children.

Authors:  Manolya Acar; Murat Sütçü; Hacer Aktürk; Selda Hançerli Törün; Metin Uysalol; Sevim Meşe; Nuran Salman; Ayper Somer
Journal:  Turk Pediatri Ars       Date:  2017-03-01

10.  Influenza-related hospitalization and ED visits in children less than 5 years: 2000-2011.

Authors:  Astride Jules; Carlos G Grijalva; Yuwei Zhu; H Keipp Talbot; John V Williams; Katherine A Poehling; Sandra S Chaves; Kathryn M Edwards; William Schaffner; David K Shay; Marie R Griffin
Journal:  Pediatrics       Date:  2014-12-08       Impact factor: 7.124

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.